Afatinib clinical trials
Also written BIBW 2992, Giotrif, Gilotrif and (2E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydrofuran-3-yl)oxy)quinazolin- 6-yl)-4-(dimethylamino)but-2-enamide bis(hydrogen (2Z)-but-2-enedioate).
How each study uses Afatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Afatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 12 Jul 2013 · GILOTRIF · NDA 201292 (FDA, Drugs@FDA)
- European Union
- 25 Sept 2013 · Giotrif · EMEA/H/C/002280 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
160 studies that test it; most in 2015 (17)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 2 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 10 |
| 2010 | 8 |
| 2011 | 11 |
| 2012 | 14 |
| 2013 | 12 |
| 2014 | 7 |
| 2015 | 17 |
| 2016 | 11 |
| 2017 | 7 |
| 2018 | 7 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 66 · Other 94
Boehringer Ingelheim (65) · West China Hospital (4) · Massachusetts General Hospital (4) · National Cancer Institute (NCI) (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · The Netherlands Cancer Institute (3) · Yonsei University (3) · H. Lee Moffitt Cancer Center and Research Institute (2)
Often tested with
Tested in the same studies.
Palbociclib (6) · Nintedanib (5) · Pembrolizumab (4) · Paclitaxel (4) · Dasatinib (3) · Nivolumab (3) · Osimertinib (3) · Cetuximab (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test Afatinib.
- Dec 2026A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaPhase 2 · Yale University
- Dec 2026AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCPhase 4 · Michael Hopp
- Feb 2027Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- May 2027A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaPhase 1/2 · West China Hospital
- Jul 2027Pilot Trial for Treatment of Recurrent GlioblastomaEarly Phase 1 · AHS Cancer Control Alberta
- Sep 2027A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaPhase 1/2 · West China Hospital
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses Afatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 160
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationEarly Phase 1AHS Cancer Control AlbertaNCT05432518Written as Afatinib
- Pemigatinib + Afatinib in Advanced Refractory Solid TumorsRecruitingPhase 1Massachusetts General HospitalNCT06302621Written as Afatinib
- A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaRecruitingPhase 2Yale UniversityNCT02491099Written as Afatinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Afatinib + Toripalimab
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingPhase 1/2Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNCT06648096Written as Afatinib
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingPhase 3Region SkaneNCT06486142Written as Afatinib/Dacomitinib
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 1/2West China HospitalNCT06753747Written as Afatinib(30mg)
- Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR MutationsRecruitingPhase 2National University Hospital, SingaporeNCT06062823Written as Afatinib 40 MG
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT04183712Written as Afatinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Afatinib
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingPhase 2AIPING ZHOUNCT05865132Written as Afatinib
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingPhase 2Peking UniversityNCT05818982Written as Afatinib
- Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingPhase 2Qingdao Central HospitalNCT05267288Written as afatinib
- Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingPhase 2Huashan HospitalNCT05519917Written as Afatinib
- Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerActive, not recruitingPhase 1/2Jeeyun LeeNCT06085755Written as Afatinib
- Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439136Written as Afatinib Dimaleate
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Afatinib
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnPhase 1West China HospitalNCT06741982Written as Afatinib
- Afatinib in NSCLC With HER2 MutationCompletedPhase 2ETOP IBCSG Partners FoundationNCT02369484Written as Afatinib
See all 160 studies that test Afatinib →
Given beside what is tested · 22 — Afatinib is usual care or a partner of the new treatment
- Primary Tumor Resection With EGFR TKI for Stage IV NSCLCRecruitingPhase 2National Taiwan University HospitalNCT05215548Written as Afatinib
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingPhase 1/2Mirati Therapeutics Inc.NCT03785249Written as Afatinib
- A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.CompletedPhase 2West China HospitalNCT07040956Written as Afatinib
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedPhase 2/3SWOG Cancer Research NetworkNCT02438722Written as Afatinib Dimaleate
- Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersTerminatedPhase 2Partner Therapeutics, Inc.NCT05588609Written as Afatinib Oral Tablet
- Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCCWithdrawnPhase 2West China HospitalNCT06804850Written as Afatinib
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Afatinib
- Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaCompletedPhase 2West China HospitalNCT05517330Written as Afatinib
- Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Boehringer IngelheimNCT02191891Written as Afatinib
- Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedPhase 2West China HospitalNCT05516589Written as Afatinib
- Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.CompletedPhase 1Boehringer IngelheimNCT01649271Written as afatinib
- BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedPhase 2National Health Research Institutes, TaiwanNCT04839471Written as BI-754091 plus afatinib
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Afatinib
- Cambridge Brain Mets Trial 1TerminatedPhase 1/2Cambridge University Hospitals NHS Foundation TrustNCT02768337Written as Afatinib
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as Afatinib
- Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerCompletedPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT02716311Written as Afatinib
- BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLCCompletedPhase 2National Cancer Center, KoreaNCT01156545Written as BIBW 2992
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownPhase 2Baodong QinNCT03239015Written as Afatinib
- JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownPhase 1Peking UniversityNCT05164848Written as Afatinib
- Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownPhase 2Peking UniversityNCT04880811Written as Afatinib
Showing 20 of 22.
As the comparator · 1 — what is tested is compared with Afatinib
Codes
What other systems call Afatinib · ClinicalTrials.gg INT006789
- MeSH (NLM) D000077716AfatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 41UD74L59MAFATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1430438Confirmed FDA, Wikidata
- Wikidata Q4688818afatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66940AfatinibOne source FDA
- DrugBank DB08916One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077716 | Afatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 41UD74L59M | AFATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1430438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4688818 | afatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66940 | Afatinib | One source FDA |
| DrugBank | DB08916 | — | One source Wikidata |
Also registered as afatinib dimaleate (UNII V1T5K7RZ0B · RxNorm 1430441).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.